Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GLSINASDAQ:LYELNASDAQ:SBOTNASDAQ:THTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLSIGreenwich LifeSciences$10.10-2.5%$10.50$8.06▼$18.75$134.07M1.7645,597 shs26,278 shsLYELLyell Immunopharma$0.48+10.0%$0.54$0.39▼$2.88$127.62M-0.261.04 million shs1.02 million shsSBOTStellar Biotechnologies$6.45-2.9%$59,624.23$0.75▼$3.25$34.38MN/A2.95 million shs2.24 million shsTHTXTheratechnologies$2.84-1.0%$1.86$1.08▼$3.13$130.58M1.11793,422 shs329,671 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLSIGreenwich LifeSciences+3.19%+7.58%+1.37%-21.81%-17.78%LYELLyell Immunopharma-2.02%-6.07%-20.16%-25.47%-80.80%SBOTStellar Biotechnologies+2.15%+28.43%+5.56%-62.08%+122.07%THTXTheratechnologies0.00%+5.13%+91.33%+80.73%+111.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGLSIGreenwich LifeSciences1.8436 of 5 stars3.50.00.00.02.53.30.0LYELLyell Immunopharma3.3902 of 5 stars2.83.00.00.03.55.01.3SBOTStellar BiotechnologiesN/AN/AN/AN/AN/AN/AN/AN/ATHTXTheratechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGLSIGreenwich LifeSciences 3.00Buy$39.00286.14% UpsideLYELLyell Immunopharma 1.50Reduce$1.00110.44% UpsideSBOTStellar Biotechnologies 0.00N/AN/AN/ATHTXTheratechnologies 4.00Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest SBOT, GLSI, THTX, and LYEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025GLSIGreenwich LifeSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$38.00 ➝ $39.004/16/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.004/11/2025THTXTheratechnologiesJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy3/13/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.002/14/2025THTXTheratechnologiesResearch CapitlSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy2/11/2025GLSIGreenwich LifeSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.52 per shareN/ALYELLyell Immunopharma$61K2,300.73N/AN/A$2.60 per share0.18SBOTStellar Biotechnologies$210K163.71N/AN/A$2.12 per share3.04THTXTheratechnologies$88.67M1.47N/AN/A($0.45) per share-6.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGLSIGreenwich LifeSciences-$8.89M-$1.20N/AN/AN/AN/A-185.12%-164.27%N/ALYELLyell Immunopharma-$234.63M-$1.31N/AN/AN/A-323,792.09%-34.64%-30.02%5/5/2025 (Estimated)SBOTStellar Biotechnologies-$5.03M-$1.76N/AN/AN/A-1,782.64%-51.12%-48.37%N/ATHTXTheratechnologies-$23.96M-$0.08N/A40.57N/A-3.75%N/A-4.31%7/9/2025 (Estimated)Latest SBOT, GLSI, THTX, and LYEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025LYELLyell Immunopharma-$0.19N/AN/AN/AN/AN/A4/15/2025Q4 2024GLSIGreenwich LifeSciences-$0.21-$0.61-$0.40-$0.61N/AN/A3/12/2025Q4 2024LYELLyell Immunopharma-$0.20-$0.72-$0.52-$0.72N/A$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/ALYELLyell ImmunopharmaN/AN/AN/AN/AN/ASBOTStellar BiotechnologiesN/AN/AN/AN/AN/ATHTXTheratechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGLSIGreenwich LifeSciencesN/A6.916.91LYELLyell ImmunopharmaN/A13.4313.43SBOTStellar BiotechnologiesN/A9.248.96THTXTheratechnologiesN/A1.080.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGLSIGreenwich LifeSciences4.16%LYELLyell Immunopharma66.05%SBOTStellar Biotechnologies1.69%THTXTheratechnologiesN/AInsider OwnershipCompanyInsider OwnershipGLSIGreenwich LifeSciences51.67%LYELLyell Immunopharma25.10%SBOTStellar Biotechnologies7.80%THTXTheratechnologiesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGLSIGreenwich LifeSciences313.27 million6.35 millionNot OptionableLYELLyell Immunopharma270295.34 million218.83 millionOptionableSBOTStellar Biotechnologies255.33 millionN/ANot OptionableTHTXTheratechnologies14045.98 millionN/AOptionableSBOT, GLSI, THTX, and LYEL HeadlinesRecent News About These CompaniesTheratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 OfferApril 18, 2025 | seekingalpha.comIs Theratechnologies Inc. (THTX) the Best Rising Penny Stock to Buy According to Analysts?April 18, 2025 | msn.comResearch Analysts Set Expectations for THTX FY2025 EarningsApril 18, 2025 | marketbeat.comWhat is Leede Financial's Estimate for THTX FY2026 Earnings?April 17, 2025 | marketbeat.comShort Interest in Theratechnologies Inc. (NASDAQ:THTX) Rises By 2,740.1%April 16, 2025 | marketbeat.comTheratechnologies to further evaluate potential sale of the companyApril 16, 2025 | markets.businessinsider.comTheratechnologies Provides Update on Sale ProcessApril 15, 2025 | financialpost.comTheratechnologies Provides Update on Sale ProcessApril 15, 2025 | globenewswire.comTheratechnologies Engages in Exclusive Acquisition TalksApril 15, 2025 | tipranks.comSoleus Capital Issues Letter to The Board of TheratechnologiesApril 12, 2025 | financialpost.comSoleus Capital Issues Letter to The Board of TheratechnologiesApril 12, 2025 | businesswire.comTheratechnologies Responds to Future Pak's Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the CompanyApril 11, 2025 | globenewswire.comFuture Pak submits proposals to acquire TheratechnologiesApril 11, 2025 | msn.comFuture Pak Submits Proposals to Acquire Theratechnologies Inc. ...April 11, 2025 | gurufocus.comFuture Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total ValueApril 11, 2025 | businesswire.comTheratechnologies Stock Plummets On Disappointing Q1 Earnings, Full Year Forecast: Retail Sentiment SoursApril 9, 2025 | msn.comTheratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key AchievementsApril 9, 2025 | globenewswire.comTheratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key AchievementsApril 9, 2025 | globenewswire.comTheratechnologies receives FDA approval of PAS for EGRIFTA SV sBLAApril 8, 2025 | markets.businessinsider.com3THTX : Examining the Future: Theratechnologies's Earnings OutlookApril 8, 2025 | benzinga.comTheratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLAApril 8, 2025 | financialpost.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSBOT, GLSI, THTX, and LYEL Company DescriptionsGreenwich LifeSciences NASDAQ:GLSI$10.10 -0.26 (-2.51%) As of 04:00 PM EasternGreenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Lyell Immunopharma NASDAQ:LYEL$0.48 +0.04 (+9.97%) As of 04:00 PM EasternLyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Stellar Biotechnologies NASDAQ:SBOTStellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company's products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.Theratechnologies NASDAQ:THTX$2.84 -0.03 (-1.05%) As of 04:00 PM EasternTheratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
